Skip to content
Back to search results

St. George's Respiratory Questionnaire

Introduced by
Paul W. Jones, King's College London
Year
1991
Type
Self-report questionnaire
Family
respiratory-qol
Font size

What does it do?

The SGRQ is a 76-item disease-specific quality-of-life instrument designed to measure health status in patients with chronic respiratory disease, particularly chronic obstructive pulmonary disease (COPD).

Developed by Jones and colleagues at King's College London in 1991, it has become the gold standard for assessing functional impact and symptom burden in respiratory populations. The SGRQ is widely used in clinical trials, epidemiological studies, and routine respiratory care to track changes in patient-reported outcomes.

The intuition behind the method

The SGRQ was constructed specifically to capture the unique patient experience in chronic respiratory disease—beyond simple lung function measures. It recognizes that airway obstruction affects multiple life domains: physical function, emotional well-being, and social participation. Rather than generic health status items, each SGRQ item targets respiratory-specific impacts: breathing limitations during daily activities, sleep disruption due to cough or dyspnea, social restrictions due to respiratory symptoms, and emotional responses to disease burden. This targeted approach ensures sensitivity to clinically meaningful changes in respiratory patients.

History

Paul W. Jones and colleagues developed the SGRQ at King's College London, first published in 1991 as a disease-specific measure complementing the generic SF-36. The original validation study (Jones et al. 1992) demonstrated superior responsiveness compared to generic instruments in COPD populations. The SGRQ has since become the most widely used disease-specific respiratory QoL measure globally, with translations in >30 languages. Later developments include the SGRQ-C (categorical version for simplicity) and digital administration formats.

When to use it

The SGRQ is indicated for patients with chronic respiratory conditions, particularly COPD, cystic fibrosis, bronchiectasis, interstitial lung disease, and asthma. It is preferred in clinical research, especially pharmacological or rehabilitative trials, where disease-specific outcomes are essential. The SGRQ can also monitor longitudinal disease progression in routine clinical practice. It is less suitable for acute respiratory conditions or patients unable to read/understand self-report items.

Limitations and considerations

  • Length (76 items) may burden patients in routine clinical practice with limited time or cognitive fatigue
  • Requires literacy: Self-completion assumes adequate reading ability; no oral administration guidance provided
  • Ceiling/floor effects in some subgroups: Mild disease or near-remission patients may show limited score variance

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Disease-specific: Captures respiratory-relevant impacts on daily living, not generic health concepts
  • Psychometrically robust: Extensively validated, with established reliability (test–retest r>0.70), construct validity, and responsiveness to change
  • Sensitive to clinically meaningful change: MCID well-established (4 points), allowing precise detection of improvement or deterioration
  • Multicultural adaptations: Available in numerous languages with validated translations, facilitating international research and clinical use

Applications

  • Clinical trials: Primary or secondary endpoint in COPD, asthma, and cystic fibrosis drug efficacy studies to quantify patient-relevant benefits
  • Pulmonary rehabilitation programs: Pre–post outcome measurement to document functional gains from exercise and education interventions
  • Epidemiological research: Population-level assessment of respiratory disease burden and impact of environmental exposures or comorbidities
  • Routine clinical monitoring: Longitudinal tracking in clinic to inform treatment adjustments and detect deterioration warranting intervention

How it works

How it works

1

The SGRQ comprises 76 items organized into three components: Symptoms (8 items, weighted), Activity (16 items weighted by impact), and Impacts (50 items on general functioning, social isolation, and emotional consequences). Items use varied response formats: some yes/no dichotomous, others ranked frequency-based (e.g., 'nearly every day' to 'not at all'). The questionnaire is self-completed, typically requiring 10–15 minutes. No special training is required; administration can occur in clinic, by mail, or electronically.

Formula
Respondent completes 76-item self-administered questionnaire
2

Scoring involves weighted calculation by component. The Symptoms component counts relevant items; Activity and Impacts components use weighted scoring reflecting relative importance. Raw scores for each component are converted to a 0–100 scale (lower is better). A Total score is then calculated as a weighted average of the three components, also ranging 0–100. Minimal clinically important difference (MCID) is approximately 4 units; a change of ≥4 points is considered clinically relevant.

Formula
Raw scores transformed to 0–100 scale; three component scores calculated
3

SGRQ Total Score interpretation: 0–25 = mild respiratory impact, 26–50 = moderate impact, 51–75 = marked impact, >75 = severe respiratory limitation. Higher scores reflect greater impairment in quality of life. Clinical decision-making considers both absolute score (baseline burden) and change score (response to intervention). In clinical trials, responders are typically defined as ≥4-point improvement; deterioration of similar magnitude warrants clinical attention.

Formula
Higher scores indicate greater impairment; MCID threshold applied

Common pitfalls

  • Using a single time point without baseline context: Always compare individual scores against prior measurement to assess meaningful change
  • Misinterpreting raw scores without understanding weighting: Raw item counts differ from final component scores; always use the weighted transformed scale
  • Ignoring component breakdown: Total score alone obscures which domain (Symptoms, Activity, or Impacts) is most affected; review all three for comprehensive clinical picture

Frequently asked questions

How long does the SGRQ take to complete?

Typically 10–15 minutes for most respondents. Patients with severe dyspnea or cognitive impairment may require additional time or assistance.

What score change indicates clinically meaningful improvement?

A reduction of ≥4 points on the 0–100 Total scale is considered the minimum clinically important difference (MCID). In group studies, a 4-point mean difference would signal a detectable treatment effect.

Is the SGRQ suitable for asthma-only patients, or is it COPD-specific?

While developed in COPD, the SGRQ has been validated in asthma, cystic fibrosis, and bronchiectasis. However, the emphasis on chronic activity limitation may be less sensitive in mild intermittent asthma; consider the Asthma Control Questionnaire for asthma-specific monitoring.

How do I score the SGRQ if a respondent skips items?

Item imputation procedures exist for missing data; typically, missing items in a subscale are estimated using the mean of completed items in that subscale. However, if >10% of items are missing, the questionnaire should be considered invalid.

Related methods

Sources

  1. Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991). The St George's Respiratory Questionnaire. Respiratory Medicine, 85(Suppl B), 25-31.

    Open DOI reference
    Copied.
  2. Jones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992). A self-complete measure of health status for chronic airflow limitation: The St. George's Respiratory Questionnaire. American Review of Respiratory Disease, 145(6), 1321-1327.

    Open DOI reference
    Copied.